We provide you with 20 years of free, institutional-grade data for CGTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CGTX. Explore the full financial landscape of CGTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Cognition Therapeutics Inc.(NASDAQ:CGTX) 
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 recept...
Website: http://www.cogrx.com
Founded: 2007
CEO: Hank Safferstein
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about CGTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.